RESEARCH ARTICLE

Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test

Marco Andrey C. Frade¹*, Natália A. de Paula¹, Ciro M. Gomes¹,²*, Sebastian Vernal¹*, Fred Bernardes Filho¹¹, Helena B. Lugão¹, Marilda M. M. de Abreu³,²*, Patrícia Botini³,², Malcolm S. Duthie⁴*, John S. Spencer⁵*, Rosa Castália F. R. Soares⁶*, Norma T. Foss¹*

¹ Dermatology Division, Department of Medical Clinics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil, ² Dermatology Division, Department of Medical Clinics, Faculty of Medicine, University of Brasília, Brasília, Brazil, ³ Service of Dermatology, University of Oeste Paulista, Presidente Prudente, Brazil, ⁴ Infectious Diseases Research Institute, 1616 Eastlake Av. E, Seattle, WA, United States of America, ⁵ Colorado State University, Department of Microbiology, Immunology and Pathology, Fort Collins, CO, United States of America, ⁶ General Coordination of Leprosy and Eliminating Diseases, Surveillance Secretariat in Health, Brazilian Health Ministry, Brasília, Distrito Federal, Brazil

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work

OPEN ACCESS

Citation: Frade MAC, de Paula NA, Gomes CM, Vernal S, Bernardes Filho F, Lugão HB, et al. (2017) Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test. PLoS Negl Trop Dis 11(2): e0005375. doi:10.1371/journal.pntd.0005375

Abstract

Background

Leprosy diagnosis is mainly based on clinical evaluation, although this approach is difficult, especially for untrained physicians. We conducted a temporary campaign to detect previously unknown leprosy cases in midwestern Brazil and to compare the performance of different serological tests.

Methods

A mobile clinic was stationed at the main bus terminal in Brasília, Brazil. Volunteers were quizzed and given a clinical exam to allow categorization as either patients, known contacts of patients or non-contacts, and blood was collected to determine anti-PGL-I and anti-LID-1 antibody titers by ELISA and by the NDO-LID rapid test. New cases of leprosy and the impact of performing this broad random surveillance strategy were evaluated. Accuracy values and concordance between the test results were evaluated among all groups.

Results

Four hundred thirty-four individuals were evaluated, and 44 (10.1%) were diagnosed with leprosy. Borderline forms were the most frequent presentation. Both tests presented higher positivity in those individuals with multibacillary disease. Serological tests demonstrated specificities around 70% for anti-PGL-1 and anti-LID ELISA; and around 40% for NDO-LID. Sensitivities ranged from 48 to 62%. A substantial agreement between NDO-LID and
ELISA with concomitant positive results was found within leprosy patients (Kappa index = 0.79 CI95% 0.36–1.22).

Conclusions
The unexpectedly high leprosy prevalence in this population indicates ongoing community-based exposure to *Mycobacterium leprae* antigens and high rates of subclinical infection. All tests showed low specificity and sensitivity values and therefore cannot be considered for use as stand-alone diagnostics. Rather, considering their positivity among MB patients and non-patients, these tests can be considered effective tools for screening and identifying individuals at high risk who might benefit from regular monitoring.

Author summary
Leprosy is a disease that affects the skin and peripheral nervous system, caused by *Mycobacterium leprae* (*M. leprae*), that to survive hides itself within the host cells and grows slowly. Its diagnosis is difficult and requires trained physicians. Laboratorial tests are frequently negative depending on individual response. *M. leprae* transmission is mainly man to man, because this is very important diagnosis and treatment of patients for breaking the transmission chain. We conducted a temporary campaign to detect previously unknown leprosy cases in midwestern Brazil and to compare the performance of different serological tests (anti-PGL-I and anti-LID-1 antibody titers by ELISA and by the NDO-LID rapid test). Four hundred thirty-four individuals were evaluated, and 44 (10.14%) were diagnosed with leprosy. Each test presented higher positivity in those individuals with multibacillary disease. For leprosy diagnosis, serological tests demonstrated specificities around 70% for anti-PGL-1 and anti-LID ELISA; and around 40% for NDO-LID. Sensitivities ranged from 48 to 62%. Anti-PGL-1 and anti-LID-1 ELISA sensitivity values were 30.1% and 23.7% respectively, while NDO-LID sensitivity was 51.6% among contacts and non-contacts. The low specificity and sensitivity values of serological tests establish that they cannot be considered stand-alone diagnostics considering the importance of clinical manifestations in leprosy. Rather, we suggest using such tests as a means to triage potential patients for follow-up clinical examinations.

Introduction
Leprosy diagnosis is mainly based on clinical evaluation [1]. This approach represents a low-cost strategy; however, it is subjective and dependent upon the experience of the examiner, a difficult task for untrained physicians [2].

Early recognition is critical for the prompt initiation of multidrug therapy (MDT) to prevent irreversible adverse outcomes [1]. Although the number of new cases registered annually by the leprosy surveillance program of the World Health Organization (WHO) have been dramatically reduced since the introduction of multidrug therapy, MDT [3], endemic leprosy pockets linger in countries such as Brazil, India and Indonesia, and current case detection strategies require clinical expertise for diagnosis. Many national leprosy-specific control programs have been integrated into the general health system to facilitate patient care. Nevertheless, these control programs have not reduced the expected number of new cases, as they have
been implemented in high endemic countries, where the actual number of cases is 6-8-fold higher than currently reported [4]. The present recommendation is to extend surveillance following the “index” case and to examine close contacts [5], particularly those who are blood relatives of multibacillary (MB) patients [6]. Not only are the logistics of such an approach extremely difficult, such activities are complicated by the need to recognize an index case to trigger them.

Bacilloscopy, histopathological examination, serology and polymerase chain reaction are used to recognize leprosy [7, 8]. Phenolic glycolipid-I (PGL-I) is a specific antigen from Mycobacterium leprae (M. leprae) that induces the formation of IgM class antibodies [9]. Anti-PGL-I antibodies are found in high concentrations in the sera of MB patients [9] and are correlated with the bacterial index [10, 11]. This specific humoral response has been investigated as an auxiliary tool for diagnosis [12, 13], although its utility in active surveillance remains uncertain [14]. Antibody responses to other antigens, such as Leprosy IDRI Diagnostic (LID)-1 protein, a fusion of two well-recognized M. leprae proteins (ML0405/ML2331) [15], have been studied to improve the accuracy of serological tests [16, 17]. Therefore, the combination of anti-LID-1 IgG and anti-PGL-I IgM detection is a strategy to improve test sensitivity in the entire clinical spectrum of disease [18]. Similarly, NDO-LID, a commercial immunochromatographic lateral flow test, has been developed to detect anti-PGL-I and anti-LID1 antibodies for initial clinical screening [19, 20] and is applied easily in the field with minimal training.

In the current study, we conducted clinical examinations during a brief active campaign in midwestern Brazil to determine the extent of undiagnosed leprosy. In parallel, we tested all individuals using and comparing three leprosy serological methods: anti-PGL-I and anti-LID-1 by ELISA and the NDO-LID commercial rapid diagnostic test (RDT).

**Methods**

**Screening**

A mobile clinic was established from January 13th to 17th, 2014, during a diagnosis campaign in a bus terminal of Brasilia, Federal District (FD), Brazil. After a broad recruitment strategy (radio, television and banner advertisements), individuals were enrolled by health care agents if they presented just any general symptoms of leprosy and/or had knowingly been in contact with someone with leprosy.

**Clinical evaluation**

The enrolled individuals underwent a clinical dermatological-neurological exam by dermatologist. Leprosy diagnosis was made by the finding of at least one of the following signs: (A) Definite loss of sensitivity and/or some dysautonomia in a pale (hypopigmented) or reddish skin patch or (B) peripheral nerve impairment with respective loss of sensitivity and/or muscle weakness [1]. All leprosy diagnoses were certified by at least two experts. Leprosy patients were classified based on the Ridley-Jopling classification [21] modified according to the following forms: indeterminate (I), polar tuberculoid (TT), borderline tuberculoid (BT), borderline (BB), borderline lepromatous (BL) and polar lepromatous (LL), and according to WHO operational criteria (paucibacillary, PB (I and TT patients) and multibacillary, MB (Borderline forms and LL patients)), and they were referred to a health unit for standard MDT.

**Laboratory evaluation**

Blood was collected and the antibody response was assessed using the commercial RDT (NDO-LID, Orange Life, Rio de Janeiro, Brazil) and also with an antigen-specific antibody
ELISA. A specialized immunologist, who was blinded to the patient’s condition, performed the ELISA reactions and analyzed the results.

**NDO-LID.** One drop of total blood (10–20 μl) collected by venopuncture was placed into the well following the manufacturer’s instructions. The NDO-LID results were considered positive or negative when the test strip was photographed, read, and analyzed by the Smart Reader application device (NDO-LID SR, Orange Life, Rio de Janeiro, Brazil). Additionally, the NDO-LID results were scored visually by three independent evaluators using qualitative (positive or negative) and semi-quantitative (0, 1+, 2+) scores. The final qualitative results were set when at least two evaluators agreed with a result. The final semi-quantitative results were considered as the mean value from the visual scores of each evaluator.

**Anti-PGL-I and anti-LID-1 ELISA.** ELISA microplate wells were coated overnight with antigens, synthetic PGL-I (12.5 ng/well ND-O-BSA) or LID-1 (50 ng/well) antigen in 0.1M carbonate/bicarbonate pH 9.6 coating buffer (50 μl). Following blocking with blocking buffer (1% bovine serum albumin in phosphate buffered saline pH 7.2 with 0.05% Tween, 1% BSA/ PBS/T) for 1 hour, sera were diluted in this same blocking solution, tested at a 1:400 dilution (100 μl) and subsequently incubated for 2-h at room temperature (RT). Then, the wells were washed with PBS with 0.05% Tween20 (PBS/T, wash buffer) six times. Secondary peroxidase-conjugated anti-human IgM (anti-PGL-I) or anti-human IgG (anti-LID-1) (1:20,000, Abcam, Cambridge, UK) was added for another 2-h incubation period. Following this incubation, the wells were washed with PBS/T six times followed by the addition of 100 μl of substrate (3,3′,5,5′-tetramethylbenzidine; TMB). After 15-minutes at RT-incubation, 50 μl of stop solution (H₂SO₄, 1 M) was added. Optical density (OD) values were determined with an ELISA plate reader (Asys Expert Plus-Microplate Reader UK) at 450 nm.

For anti-LID-1 ELISA positivity, the cut-off (0.100) was calculated from the OD average among 18 healthy subjects multiplied by five. For the anti-PGL-I ELISA, the cut-off (0.608) was based on the OD average among healthy subjects multiplied by 2.1 plus 10%, as previously described [15, 22].

In both ELISAs, the respective index was calculated by dividing the OD of each sample by the cut-off [15, 22], and indexes above 1.0 were considered positive.

**Statistical analysis**

Categorical variables between the groups were compared using the Chi-square (χ²) test. Fisher’s exact test was used when data were sparse. Using the NDO-LID result as a reference, an inter-rater agreement between the tests was performed (Kappa index: <0 = no agreement, 0–0.19 = poor, 0.2–0.39 = fair, 0.4–0.59 = moderate, 0.6–0.79 = substantial, and 0.8–1.0 = almost perfect agreement); this approach was also applied to compare the NDO-LID results by the Smart Reader and by visual reading. Significance was set at \( p < 0.05 \), with a 95% confidence interval, using two-tailed comparisons. The statistical analysis was performed using OpenEpi version 3.01 (Emory University, Rollins School of Public Health, Atlanta, Georgia, USA). Missing variables were ignored, and only patients who underwent all exams were tested for agreement.

**Ethics**

Patients were included after signing the informed consent form. Parents/guardians provided informed consent on behalf of all child participants. The study complies with the Declaration of Helsinki, as revised in 2013. This study was approved by the Ethics Committee of the Clinical Hospital of Ribeirão Preto (HCRP N˚ 16620/2014).
Results

A total of 434 individuals were evaluated, and 44 (10.1%) were diagnosed with leprosy. According to the WHO operational classification, 88.6% were classified as MB. The Borderline forms were the most represented, with 36 cases (81.8%; Fig 1; Table 1) distributed among BT (n = 5), BB (n = 24) and BL (n = 7) patients. Blood collection was performed on 381 individuals, while 53 individuals declined, including a confirmed leprosy patient. Table 2 shows the individual demographics.

Among the leprosy patients, 34 resided within FD (77.3%), whereas the remaining patients lived in either neighboring Goiás (n = 9) or Mato Grosso State (n = 1) (Fig 1A). Cases in the FD were distributed throughout at least 16 different administrative regions, with the most cases from any one administrative region being only 4 (Fig 1B). Furthermore, although more than half were originally from other states and had migrated into the Federal District (Fig 1C), the majority of patients had been in residency for extended periods of time. The 44 patients had a mean time of residency in their administrative regions of 13.5 years, and 32 of them had lived more than 5 years in the same place.

Twenty-two (50%) of the leprosy patients did not report any known leprosy patient contact. Among the individuals without any clinical signs of disease (n = 390), 99 (25.4%) had a leprosy contact, whereas 291 (74.6%) declared no known contact.

Regarding the blood samples collected from healthy individuals (n = 338), 93 (27.5%) were contacts of persons with leprosy, whereas 245 (72.5%) did not have any known contact. The results of the anti-PGL-1 and anti-LID-1 ELISA and the NDO-LID are characterized for each clinical form in Table 1. In leprosy diagnosis, considering all disease forms, each of the tests demonstrated a specificity of approximately 70% for anti-PGL-1 and anti-LID ELISA and of

![Fig 1. Residency history of leprosy cases identified in the temporary clinic.](Image)
approximately 40% for NDO-LID. Sensitivity was less than 65% in all tested techniques. (Table 3). Considering only healthy subjects (n = 338), with the aim of identifying leprosy contacts (Table 3), the sensitivity values of anti-PGL-I and anti-LID-1 ELISA were 30.11% and 23.66% respectively, while NDO-LID sensitivity was 51.61%. Specificity values were lower than 75% in all the three tests.

We observed a substantial agreement between the NDO-LID and antibody-detection ELISA (anti-PGL-I plus anti-LID-1), with a $\kappa$ index value of 0.79 (CI 95% 0.36–1.22) for the leprosy patients. A fair agreement ($\kappa$ index between 0.19 and 0.20) was shown between the NDO-LID and ELISA assays, with concomitant results between individuals with known contact and those without. NDO-LID and the anti-PGL-I ELISA showed a moderate agreement ($\kappa$ index value (CI 95% 0.08–0.67)) and a fair agreement when the NDO-LID was compared with the anti-LID-1 ELISA (0.35 CI95% (0.06–0.63)) among the leprosy patients.

We would expect the NDO-LID titers to be represented by the reactivity to each individual component, i.e., approximating the combination of the anti-PGL-I and the anti-LID-1 titers by ELISA. The ELISAs were stratified by indices (Tables 4 and 5), and the results were compared between the results obtained by the Smart Reader and by visual reading. For ELISA

### Table 1. Clinical characterization of leprosy patients and healthy individuals (contacts or non-contacts).

| Clinical Form (Leprosy patients) | N | Positive N (%) | a-PGL-I | a-LID-1 | NDO-LID SR |
|----------------------------------|---|----------------|---------|---------|------------|
| Indeterminate (I)                | 3 | 2 (66.7)       | 1 (33.3)| 0 (0.0) |
| Tuberculoid (TT)                 | 2 | 0 (0.0)        | 2 (100) | 2 (100) |
| Borderline Tuberculoid (BT)      | 5 | 3 (60.0)       | 3 (60.0)| 4 (80.0)|
| Borderline Borderline (BB)       | 23| 11 (47.8)      | 7 (30.4)| 12 (52.2)|
| Borderline Lepromatous (BL)      | 7 | 5 (71.4)       | 5 (71.4)| 6 (85.7)|
| Lepromatous (LL)                 | 3 | 3 (100)        | 3 (100) | 3 (100) |
| TOTAL                            | 43| 24 (55.8)      | 21 (48.8)| 27 (62.8)|
| MB                               | 38| 22 (57.9)      | 18 (47.4)| 25 (65.8)|
| PB                               | 5 | 2 (40)         | 3 (60)  | 2 (40)  |
| TOTAL                            | 43| 24 (55.8)      | 21 (48.8)| 27 (62.8)|

Contact History (Healthy individuals)

| Contacts                        | 93| 28 (30.1) | 22 (23.7)| 48 (51.6)|
| Non-contacts                     | 245| 84 (34.3) | 67 (27.3)| 148 (60.4)|
| **TOTAL**                        | 338| 112 (33.1)| 89 (26.3)| 196 (58.0)|

### Table 2. Characterization of the individuals and patients included in the study.

|                  | Healthy Individuals (N = 390) N (%) | Patients with clinical diagnosis of Leprosy (N = 44) N (%) | P-value |
|------------------|-------------------------------------|----------------------------------------------------------|---------|
| **Sex**          |                                      |                                                          | 0.109   |
| Male             | 165 (42.3)                           | 13 (29.5)                                                |         |
| Female           | 225 (57.7)                           | 31 (70.5)                                                |         |
| **Age mean (range)** | 46 (1–87)                        | 42.1(9–73)                                               | 0.232   |
| Under 15 years old | 25 (6.4)                           | 2 (4.5)                                                  |         |
| 15 years old and older | 365 (93.6)                         | 42 (95.5)                                                |         |
| **State of residency** |                                           |                                                          | 0.110   |
| Federal District | 338 (86.7)                           | 34 (77.3)                                                |         |
| Other State      | 52 (13.3)                            | 10 (22.7)                                                |         |

doi:10.1371/journal.pntd.0005375.t01f

doi:10.1371/journal.pntd.0005375.t002
indices < 1.0, there was much lower concordance with the response given by Smart Reader; however, for ELISA indices > 1.0, there was better agreement with the Smart Reader results. Further, there was moderate agreement (0.55 κ index (CI 95% 0.45–0.66)) between the results read with Smart Reader and the results by visual interpretation (Tables 4 and 5).

### Discussion

According to the leprosy prevalence rate, FD has been considered a non-endemic area since 2005 [23]; however, the present recruitment procedure resulted in a different scenario with a very high percentage of new cases of leprosy, similar to what one would expect from a hyper-endemic area [12, 24]. This fact can be explained by an expected high sensitivity in the screening strategies incorporating our passive random surveillance strategy. Importantly, the leprosy cases detected were not recent emigrants from areas recognized as being hyper-endemic for leprosy.

| Table 3. Accuracy of diagnosis of serological tests for leprosy. |
|---------------------------------------------------------------|
| **Leprosy Patients and Healthy Individuals**                  |
|                                                              |
| **Sensitivity**                                              |
| a-PGL-I % (CI 95%)                                          |
| 55.81% (41.11–69.57)                                        |
| a-LID-1 % (CI 95%)                                         |
| 48.84% (34.62–63.25)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 62.79% (47.86–75.62)                                        |
| **Specificity**                                             |
| a-PGL-I % (CI 95%)                                          |
| 66.86% (61.68–71.67)                                        |
| a-LID-1 % (CI 95%)                                         |
| 73.67% (68.73–78.08)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 42.01% (36.87–47.33)                                        |
| **Positive Predictive Value**                               |
| a-PGL-I % (CI 95%)                                          |
| 17.65% (12.16–24.92)                                        |
| a-LID-1 % (CI 95%)                                         |
| 19.09% (12.84–27.43)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 12.11% (8.46–17.04)                                        |
| **Negative Predictive Value**                               |
| a-PGL-I % (CI 95%)                                          |
| 92.24% (88.21–94.98)                                        |
| a-LID-1 % (CI 95%)                                         |
| 91.88% (88.01–94.58)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 89.87% (84.18–93.67)                                        |

**Contacts and Non-contacts**

| **Sensitivity**                                              |
| a-PGL-I % (CI 95%)                                          |
| 30.11% (21.73–40.07)                                        |
| a-LID-1 % (CI 95%)                                         |
| 23.66% (16.17–33.23)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 51.61% (41.60–61.50)                                        |
| **Specificity**                                             |
| a-PGL-I % (CI 95%)                                          |
| 65.71% (59.57–71.37)                                        |
| a-LID-1 % (CI 95%)                                         |
| 72.65% (66.75–77.85)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 39.59% (33.67–45.83)                                        |
| **Positive Predictive Value**                               |
| a-PGL-I % (CI 95%)                                          |
| 25.00% (17.90–33.76)                                        |
| a-LID-1 % (CI 95%)                                         |
| 24.72% (16.93–34.60)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 24.49% (19.00–30.96)                                        |
| **Negative Predictive Value**                               |
| a-PGL-I % (CI 95%)                                          |
| 71.24% (65.02–76.75)                                        |
| a-LID-1 % (CI 95%)                                         |
| 71.49% (65.58–76.73)                                        |
| NDO-LID SR % (CI 95%)                                       |
| 68.31% (60.26–75.39)                                        |

**Table 4. Distribution the positivity of NDO-LID test according to the distribution of the ELISA assay index (I).**

| Index Range (I) a-PGL-I (N) | NDO-LID SR (Positive) | % Concordance | NDO-LID Visual (Positive) | % Concordance | Kappa Index (SR x Visual) | Healthy Individuals | Patients |
|-----------------------------|-----------------------|--------------|---------------------------|--------------|---------------------------|---------------------|----------|
| 0.0 ≤ I < 1.0 (226)         | 102                   | 45.1         | 71 9 80                   | 35.5         | 1 2 15 0                  | I T B L             |
| 1.0 ≤ I < 1.5 (65)          | 51                    | 78.5         | 31 17 48                  | 73.8         | 1 0 8 0                   |                    |
| 1.5 ≤ I < 2.0 (27)          | 24                    | 88.9         | 10 10 20                  | 74.1         | 1 0 6 0                   |                    |
| I ≥ 2.0 (20)                | 19                    | 95           | 7 10 17                   | 85           | 0 0 6 3                   |                    |

| Index Range (I) a-LID-1 (N) | NDO-LID SR (Positive) | % Concordance | NDO-LID Visual (Positive) | % Concordance | Kappa Index (SR x Visual) | Healthy Individuals | Patients |
|-----------------------------|-----------------------|--------------|---------------------------|--------------|---------------------------|---------------------|----------|
| 0.0 ≤ I < 1.0 (248)         | 139                   | 56           | 89 27 116                 | 46.8         | 2 0 20 0                  | I T B L             |
| 1.0 ≤ I < 1.5 (48)          | 33                    | 68.8         | 14 13 27                  | 56.3         | 1 2 6 0                   |                    |
| 1.5 ≤ I < 2.0 (17)          | 10                    | 58.8         | 7 3 10                    | 58.8         | 0 0 4 0                   |                    |
| I ≥ 2.0 (25)                | 14                    | 56.0         | 7 4 11                    | 44           | 0 0 5 3                   |                    |

a-PGL-I = Anti-PGL-I ELISA. a-LID-1 = anti-LID-1 ELISA. NDO-LID SR = NDO-LID results from the Smart Reader application device; I = Indeterminate, T = Tuberculoid, B = Borderline, L = Lepromatous
leprosy and thus, both our clinical data and serological evaluations indicate that leprosy remains an issue, and that \textit{M. leprae} transmission continues, in FD.

Leprosy diagnosis is still essentially defined by clinical examination. However, in many cases, the changes can be subtle and are often missed even by specialists. Bacilloscopy, histopathology and serology tests can be used to assist the clinical diagnosis and are also useful in spectral and treatment categorization [25, 26]. Nevertheless, the accuracy of these tests is still debated, and many groups are searching for simple ways to make them more reliable, especially in the identification of leprosy cases among household contacts [15].

NDO-LID was shown to be positive in 62.8% of the clinically diagnosed leprosy patients, although this rapid test presented a lower specificity than anti-PGL-I and anti-LID-1 ELISA, as described in Table 3. Despite being able to identify the dominant responses to both glycolipid (IgM anti-PGL-I) and protein (IgG anti-LID-1), NDO-LID has the same limitation as the previously used RDT, showing a difficulty in screening patients in early stages of disease and/or PB forms. Regardless, the use of these tests in conjunction with, or as a trigger for, clinical examination may promote earlier detection and treatment of leprosy cases.

Our anti-PGL-I ELISA findings were similar to previously described results [13, 27, 28]. The anti-PGL-I ELISA was able to identify all LL cases (n = 3), 54.3% of borderline forms (n = 19), especially BL patients (71.4%) and 66.7% of I form. Individuals with the TT form (n = 2) were not identified. The anti-LID-1 ELISA results showed a lower percentage of positivity in borderline forms (n = 15/35, 42.9%) and indeterminate forms (n = 1/3, 33.3%). Also in borderline patients, this test performed better in BL forms, detecting a similar percentage of patients (71.4%) in comparison to anti-PGL-I ELISA. However, considering the limited number of samples tested, our data showed 100% positivity in both LL and TT forms (n = 3

| Table 5. Inter-rate agreement between tests in leprosy patients, known contacts and non-contacts. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                | \textit{a-PGL-I} (\textit{+}) N (%) | \textit{a-PGL-I} (\textit{-}) N (%) | Kappa Index \textit{(CI 95\%)} |
|                                                | \textit{a-LID-1} (\textit{+}) N (%) | \textit{a-LID-1} (\textit{-}) N (%) | |
|                                                | \textit{a-PGL-I} (\textit{+}) and \textit{a-LID-1} (\textit{+}) N (%) | \textit{a-PGL-I} (\textit{+}) and \textit{a-LID-1} (\textit{-}) N (%) | |
|                                                | \textit{a-PGL-I} (\textit{-}) and \textit{a-LID-1} (\textit{+}) N (%) | \textit{a-PGL-I} (\textit{-}) and \textit{a-LID-1} (\textit{-}) N (%) | |
| Leprosy Patients                               | 19 (44.2)                          | 8 (18.6)                          | 17 (39.5)                          |
|                                                | 10 (23.3)                          | 11 (25.5)                          | 8 (18.6)                          |
|                                                | 6 (14.0)                          | 2 (4.7)                          | |
| NDO-LID SR (+)                                | 5 (11.6)                          | 11 (25.6)                          | 0.37 (0.08–0.67)                          |
|                                                | 12 (27.9)                          | 0.35 (0.06–0.63)                          | |
|                                                | 0 (0)                          | 5 (11.6)                          | 7 (16.3)                          |
|                                                | 0.79\textsuperscript{a} (0.36–1.22) | |
| Total                                         | 43                                | 43                                | |
| Known contacts                                | 22 (23.7)                          | 26 (28.0)                          | 13 (13.9)                          |
|                                                | 35 (37.6)                          | 6 (6.5)                          | 16 (17.2)                          |
|                                                | 7 (7.5)                          | 19 (20.4)                          | |
| NDO-LID SR (+)                                | 6 (6.5)                          | 39 (41.9)                          | 0.32 (0.13–0.50)                          |
|                                                | 9 (9.7)                          | 36 (38.7)                          | 0.06 (-0.10–0.23)                          |
|                                                | 2 (2.2)                          | 4 (4.3)                          | 7 (7.5)                          |
|                                                | 32 (34.4)                          | 0.19\textsuperscript{a} (0.01–0.39) | |
| Total                                         | 93                                | 93                                | |
| Non-contacts                                  | 72 (29.4)                          | 76 (31.0)                          | 44 (18.0)                          |
|                                                | 104 (42.5)                          | 23 (9.4)                          | 49 (20.0)                          |
|                                                | 21 (8.6)                          | 6 (2.5)                          | 17 (6.9)                          |
|                                                | 68 (27.8)                          | 0.21\textsuperscript{a} (0.08–0.33) | |
| Total                                         | 245                               | 245                               | 245                               |

\textsuperscript{a}Kappa Index Calculated between \textit{a-PGL-I} positive Plus \textit{a-LID-1} positive and \textit{a-PGL-I} negative Plus \textit{a-LID-1} negative. \textit{a-PGL-I} = Anti-PGL-I ELISA. \textit{a-LID-1} = anti-LID-1 ELISA. NDO-LID SR = NDO-LID results from the Smart Reader application device.

doi:10.1371/journal.pntd.0005375.t005

leprosy and thus, both our clinical data and serological evaluations indicate that leprosy remains an issue, and that \textit{M. leprae} transmission continues, in FD.

Leprosy diagnosis is still essentially defined by clinical examination. However, in many cases, the changes can be subtle and are often missed even by specialists. Bacilloscopy, histopathology and serology tests can be used to assist the clinical diagnosis and are also useful in spectral and treatment categorization [25, 26]. Nevertheless, the accuracy of these tests is still debated, and many groups are searching for simple ways to make them more reliable, especially in the identification of leprosy cases among household contacts [15].

NDO-LID was shown to be positive in 62.8% of the clinically diagnosed leprosy patients, although this rapid test presented a lower specificity than anti-PGL-I and anti-LID-1 ELISA, as described in Table 3. Despite being able to identify the dominant responses to both glycolipid (IgM anti-PGL-I) and protein (IgG anti-LID-1), NDO-LID has the same limitation as the previously used RDT, showing a difficulty in screening patients in early stages of disease and/or PB forms. Regardless, the use of these tests in conjunction with, or as a trigger for, clinical examination may promote earlier detection and treatment of leprosy cases.

Our anti-PGL-I ELISA findings were similar to previously described results [13, 27, 28]. The anti-PGL-I ELISA was able to identify all LL cases (n = 3), 54.3% of borderline forms (n = 19), especially BL patients (71.4%) and 66.7% of I form. Individuals with the TT form (n = 2) were not identified. The anti-LID-1 ELISA results showed a lower percentage of positivity in borderline forms (n = 15/35, 42.9%) and indeterminate forms (n = 1/3, 33.3%). Also in borderline patients, this test performed better in BL forms, detecting a similar percentage of patients (71.4%) in comparison to anti-PGL-I ELISA. However, considering the limited number of samples tested, our data showed 100% positivity in both LL and TT forms (n = 3

---

PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005375 | February 23, 2017 | 8 / 12
and 2, respectively). In general, the three tests performed better in the identification of MB patients, especially in the BL and in the LL forms. Many studies showed that borderline and LL patients produce high titers of IgM against PGL-I, whereas Tuberculoid patients have low levels of specific antibody [9]. Serological tests are expected to show better responses in MB; however, such improvements remain challenging.

Vaz Cardoso et al. [20] found an anti-PGL-I sensitivity from 69.8% to 92.3% in borderline patients in contrast to our results (54.3%). These differences may be explained by recruiting differences. Although we expected a higher sensitivity in a screening campaign, we used a cross-sectional/cohort strategy in which the diagnosis of controls was previously unknown. This approach generated a more pragmatic environment, reducing sensitivity values.

In addition to the importance of achieving an early diagnosis, a systematic and qualified approach to monitoring household contacts is considered essential for breaking the transmission of M. leprae [5, 29]. Individuals in close contact with untreated MB patients have a 10% lifetime risk of eventually succumbing to leprosy [2, 9, 29–31], particularly when they are consanguineous relatives [29]. Although a positive titre to anti-PGL-I is an infection biomarker, it is not an absolute indicator of disease. Evidence indicates that substantial increases in titers to anti-PGL-I and anti-LID-1 are important indicators of progression, even in the absence of skin lesions or nerve damage [11, 15, 32]. In healthy subjects, a high anti-PGL-I and anti-LID-1 titre suggests that there is a hidden bacillary load driving the response to this antigen. Household contacts demonstrating substantial increases in titre against LID-1 and/or PGL-I should be closely monitored [29, 31].

Worobec et al. [30] reported subclinical M. leprae infection in endemic regions with anti-PGL-I antibody detected in 1.7 to 35% of all individuals. Thus, the high percentage of positivity found in our group may reflect a situation of occult prevalence with many foci of infection in the municipality because many patients may be unknown contacts of leprosy patients. Therefore, considering this rate of exposure, it was not surprising that the rates of positivity in the contact group for all three tests (52% for NDO-LID, 30% for anti-PGL-I and 24% for anti-LID-1) were fairly similar to those among individuals with no history of contact with a leprosy patient, indicative of the generally high rate of exposure in this region.

Among healthy individuals, the concordance of NDO-LID with both the Smart Reader and the visual analysis with the anti-PGL-I ELISA results increased as indices rose (until 95%). Among healthy individuals, the strongest positive responses with NDO-LID showed the best concordance with individuals with the highest anti-PGL-I ELISA index, reaching a maximum where the calculated index was >2.0 (κ = 95%). In general, individuals with very strong positive responses by NDO-LID or with the highest indices in the ELISA, particularly against LID-1, should receive more careful scrutiny during their clinical examination, and regular follow-up examinations would appear prudent.

The tests evaluated in this study demonstrated low specificity and sensitivity values, which would limit their use as stand-alone tests for leprosy diagnosis. However, the tests do appear useful for screening populations as a way to assist clinicians in patient categorization, contacts’ follow-up of patients with high titers, and to assess the risk of treatment failure. Further examination of the use of serological tests for the early diagnosis of leprosy is warranted to attempts break the cycle of M. leprae transmission. This is particularly meaningful given our clinical evidence that M. leprae infection and leprosy remain as a public health concern in FD, a region officially reported having controlled leprosy.

**Conclusion**

The unexpected high percentage of leprosy cases and the high number of individuals with positive serological responses to M. leprae antigens found in this population, previously
considered ‘nonendemic,’ revealed a greater than expected extent of subclinical and frank disease, as well as a continuous contact with *M. leprae* antigens. These data may point to faults in the health care delivery system and a lack of training by physicians working in the basic health units. Ultimately, more aggressive targeted surveillance strategies, particularly focusing on cities that may experience a large migration of people, should be considered part of a national coordinated leprosy control program.

The positivity of approximately 60% of the anti-PGL-I ELISA and NDO-LID demonstrated that each test is a potential tool to identify suspected patients. The unexpectedly high rates of positivity with NDO-LID among household contacts (50%) and non-contacts (60%) indicates the difficulties in using a single test for diagnosing leprosy.

Despite the limited sensitivity found in all of the diagnosed cases, the anti-PGL-I ELISA and NDO-LID were in complete agreement in identifying all LL and more than 50% of the borderline forms, demonstrating a possible positive impact and the relevance of this type of surveillance campaign to ultimately achieving a reduction in transmission of this disease.

Further studies are necessary to elucidate the efficacy of these serological tests in other diagnostic reference standards; nevertheless, the training of local health professionals to recognize signs of disease and epidemiological surveillance remains the primary strategy for leprosy control.

**Supporting information**

S1 Checklist. STROBE Statement. Checklist of items that should be included in reports of cross-sectional studies.

(DOC)

S1 Data Sheet. Excel with campaign’s data used for analysis.

(XLSX)

**Acknowledgments**

This study was completed only through the kind participation of volunteers and the unconditional support of all members involved and engaged in the fight against leprosy, especially the support of Ms. Marli Araújo from GAMAH and its volunteers. Additionally, we thank the SES-DP team (Diva Souza, Jandiara Cardoso Silva and Juliana S. Fontenele); Prof. Raimunda Nonato Sampaio for allowing the use of the laboratory of Dermatomycology, Faculty of Medicine, University of Brasília for sample processing; and Dr. John Spencer (Colorado State University, Fort Collins, CO, USA, recipient of a Fulbright Scholar to Brazil award 2015–2016) for considerable help in conducting the laboratory tests.

**Author Contributions**

**Conceptualization:** MACF.

**Data curation:** NAdP.

**Formal analysis:** MACF NAdP CMG SV.

**Funding acquisition:** MACF RCFRS.

**Investigation:** MACF NAdP CMG SV FBF HBL MMMdA PB RCFRS JS.

**Methodology:** MACF NAdP.

**Project administration:** MACF NTF.
Resources: MACF RCFRS.
Supervision: MACF NTF.
Validation: MACF NAdP CMG SV FBF MSD JS NTF.
Visualization: MACF NAdP CMG SV.
Writing – original draft: MACF NAdP CMG SV.
Writing – review & editing: MACF NAdP CMG SV FBF MSD JS NTF.

References

1. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006–2010. Operational guidelines. Lepr Rev. 2006; 77(3):IX, X, 1–50. PMID: 17172004
2. Cardona-Castro N, Beltrán-Alzate JC, Romero-Montoya M. Clinical, bacteriological and immunological follow-up of household contacts of leprosy patients from a post-elimination area—Antioquia, Colombia. Mem Inst Oswaldo Cruz. 2009; 104(6):935–6. PMID: 19876571
3. World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012(968):61. PMID: 22970622
4. Meima A, Smith WC, van Oortmarssen GJ, Richardus JH, Habberma JD. The future incidence of leprosy: a scenario analysis. Bull World Health Organ. 2004; 82(5):373–80. PMID: 15298228
5. Alencar CH, Ramos AN, Sena Neto SA, Murto C, Alencar MeJ, Barbosa JC, et al. (Leprosy diagnosis in municipalities other than the patients’ place of residence: spatial analysis, 2001–2009), Cad Saude Publica. 2012; 28(9):1685–98. PMID: 23033184
6. Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis. 2006; 193(3):346–53. doi: 10.1086/499278 PMID: 16388481
7. Teixeira AC, Cruvinel DL, Roma FR, Luppino LF, Resende LH, Sousa T, et al. Evaluation of the agreement between clinical and laboratory exams in the diagnosis of leprosy. Rev Soc Bras Med Trop. 2008; 41 Suppl 2:48–55.
8. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006; 19(2):338–81. doi: 10.1128/CMR.19.2.338-381.2006 PMID: 16614253
9. Moura RS, Calado KL, Oliveira ML, Bührer-Sékula S. Leprosy serology using PGL-I: a systematic review. Rev Soc Bras Med Trop. 2008; 41 Suppl 2:11–8.
10. Geluk A, Duthie MS, Spencer JS. Postgenomic Mycobacterium leprae antigens for cellular and serological diagnosis of M. leprae exposure, infection and leprosy disease. Lepr Rev. 2011; 82(4):10–21. PMID: 23888930
11. Spencer JS, Brennan PJ. The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev. 2011; 82(4):344–57. PMID: 23493275
12. Barreto JG, Guimarães LeS, Frade MA, Rosa PS, Salgado CG. High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. Mem Inst Oswaldo Cruz. 2012; 107 Suppl 1:60–7.
13. Salgado CG, Ferreira DV, Frade MA, Guimarães LeS, da Silva MB, Barreto JG. High anti-phenolic glycolipid-I IgM titers and hidden leprosy cases, Amazon region. Emerg Infect Dis. 2012; 18(5):889–90. doi: 10.3201/eid1805.111016 PMID: 22515845
14. Calado KLS, Vieira AdG, Durães S, Sékula SB, de Oliveira MLW-D-R. Seropositivity with anti-PGL-I of household and neighbours contacts of leprosy patients in an urban area. An Bras Dermatol. 2005; 80(Supl 3):S301–6.
15. Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LP, Martelli CM, et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol. 2007; 14(11):1400–8. doi: 10.1128/CVI.00299-07 PMID: 17896185
16. Alban SM, de Moura JF, Thomaz-Soccol V, Bührer Sékula S, Alvarenga LM, Mira MT, et al. Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy. PLoS One. 2014; 9(8):e106222. doi: 10.1371/journal.pone.0106222 PMID: 25170947
17. Kumar A, Parkash O, Girdhar BK. Analysis of antigens of Mycobacterium leprae by interaction to sera IgG, IgM, and IgA response to improve diagnosis of leprosy. Biomed Res Int. 2014; 2014:283278. doi: 10.1155/2014/283278 PMID: 25318126
18. Qiong-Hua P, Zhong-Yi Z, Jun Y, Yan W, Lian-Chao Y, Huan-Ying L, et al. Early Revelation of Leprosy in China by Sequential Antibody Analyses with LID-1 and PGL-I. J Trop Med. 2013; 2013:352689. doi: 10.1155/2013/352689 PMID: 23431316

19. Duthie MS, Balagon MF, Maghanoy A, Orcullo FM, Cang M, Dias RF, et al. Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy. J Clin Microbiol. 2014; 52(2):613–9. doi: 10.1128/JCM.02085-13 PMID: 24478496

20. Paula Vaz Cardoso L, Dias RF, Freitas AA, Hungria EM, Oliveira RM, Collovati M, et al. Development of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technology. BMC Infect Dis. 2013; 13:497. doi: 10.1186/1471-2334-13-497 PMID: 24152601

21. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966; 34(3):255–73. PMID: 5950347

22. Duthie MS, Ireton GC, Kanaujia GV, Goto W, Liang H, Bhatia A, et al. Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clinic Immunol. 2008; 15(10):1590–7. doi: 10.1128/CVI.00168-08 PMID: 18716007

23. Secretaria de Vigilância em Saúde (SVS), Ministry of Health, Brazil. Sistema de Informação de Agravos de Notificação (SINAN). Available. in: tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2012/d09b.def2005. Cited November 1st, 2016

24. Barreto JG, Bisanzio D, Frade MA, Moraes TM, Gobbo AR, de Souza Guimarães L, et al. Spatial epidemiology and serologic cohorts increase the early detection of leprosy. BMC Infect Dis. 2015; 15:527. doi: 10.1186/s12879-015-1254-8 PMID: 26573912

25. Bhatia AS, Katoch K, Narayanan RB, Ramu G, Mukherjee A, Lavania RK. Clinical and histopathological correlation in the classification of leprosy. Int J Lepr Other Mycobact Dis. 1993; 61(3):433–8. PMID: 8228443

26. Worobec SM. Current approaches and future directions in the treatment of leprosy. Res Rep Trop Med. 2012; 3:79–91.

27. Da Silva RC, Lyon S, Lyon AC, Grossi MA, Lyon SH, Bührer-Sêkula S, et al. Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy. Trans R Soc Trop Med Hyg. 2010; 104(8):546–50. doi: 10.1111/j.1365-3156.2010.02621.x PMID: 20621218

28. Silva RC, Lyon S, Araos R, Lyon AC, Grossi MA, Lyon SH, et al. The result patterns of ML Flow and ELISA (PGL-I) serologic tests in leprosy-endemic and non-endemic areas. Rev Soc Bras Med Trop. 2008; 41 Suppl 2:19–22.

29. Bazan-Furini R, Motta AC, Simão JC, Tarquínio DC, Marques W, Barbosa MH, et al. Early detection of leprosy by examination of household contacts, determination of serum anti-PGL-1 antibodies and consanguinity. Mem Inst Oswaldo Cruz. 2011; 106(5):536–40. PMID: 21894372

30. Worobec SM. Treatment of leprosy/Hansen’s disease in the early 21st century. Dermatol Ther. 2009; 22(6):518–37. doi: 10.1111/j.1529-8019.2009.01274.x PMID: 19889136

31. Brasil MTLRF, de Oliveira LR, Rimoli NS, Cavallari S, Gonçalves OS, Lessa ZL, et al. Anti-PGL-1 serology and the risk of leprosy in a highly endemic area in the State of São Paulo, Brazil: four-year follow-up. Rev Bras Epidemiol. 2003; 6(3):262–71.

32. Spencer JS, Duthie MS, Geluk A, Balagon MF, Kim HJ, Wheat WH, et al. Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz. 2012; 107 Suppl 1:79–89.